About TPD

Targeted Protein Degradation (TPD) has emerged as an exciting new modality in small molecule drug discovery with more degraders in the clinic than ever before. Despite this, degrader R&D is currently limited by low-throughput screening tools, a lack of robustness and repeatability.

With proof of concept and proof of biology now a reality for TPD, the time has come to evaluate the toolbox to accelerate degrader R&D and address the urgent need for high-throughput screening methods of monitoring TPD that are efficient, robust, sensitive, quantifiable, and reproducible.

Top Sessions You Cannot Miss:

https://tpd-assays-screening.com/wp-content/uploads/sites/811/2022/07/cropped-favicon.png

Historically, molecular glues have been discovered by serendipity however with new tools emerging, rational discovery could become a reality. Hear from Stanford University, Seed Therapeutics & University of Pittsburgh as they disclose their exciting technologies towards rational design

https://tpd-assays-screening.com/wp-content/uploads/sites/811/2022/07/cropped-favicon.png

Establish a framework for assay and screening strategies to ensure robustness, reproducibility, selectivity and understanding what key questions should be asked when to ensure success with Harvard Medical School & Dana-Farber Cancer Institute

https://tpd-assays-screening.com/wp-content/uploads/sites/811/2022/07/cropped-favicon.png

Expand the E3 ligase toolbox to move beyond VHL and cereblon to reach hard-to-drug targets by delving into mass spectrometry, phenotypic screens and proximity biotinylation with Phoremost, Plexium & UT Health San Antonio

https://tpd-assays-screening.com/wp-content/uploads/sites/811/2022/07/cropped-favicon.png

Uncover the predictive power of using 3 coordinated assays to assess ternary complex formation and whether the structure leads to targeted degradation, and importantly understanding why some ternary complex don’t lead to degradation with Monte Rosa Therapeutics & Jude Children’s Research Hospital